PCK2 as a Prognostic Biomarker in Glioblastoma
Author Information
Author(s): Yi Li, Jiang Cheng, Guo Peiquan, Zhu Wende, Jiang Xiaobing
Primary Institution: Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Hypothesis
PCK2 expression correlates with immune infiltration and prognosis in glioblastoma patients.
Conclusion
PCK2 is a promising prognostic biomarker that correlates with dendritic cell infiltration and poor outcomes in glioblastoma.
Supporting Evidence
- PCK2 is increasingly expressed in GBM tissues and serves as an independent poor prognostic indicator.
- PCK2 correlates with immune infiltrates and immunosuppression in glioblastoma.
- PCK2 is preferentially expressed in the mesenchymal subtype of glioblastoma.
- High PCK2 expression is associated with shorter overall survival in glioma patients.
Takeaway
This study found that a protein called PCK2 is linked to how well glioblastoma patients do, especially in relation to immune cells that help fight tumors.
Methodology
The study analyzed PCK2 expression in glioma cohorts using survival analysis, regression analysis, and immunohistochemistry.
Participant Demographics
The study included 539 glioblastoma patients from multiple databases.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website